ALKBH5 gene polymorphisms and Wilms tumour susceptibility in children from East China: a case–control study Authors: Jiabin Yu, Yizhen Wang, Shouhua Zhang, Haixia Zhou, Shaohua He, Ruixi Hua, Wanfu Li, Chunlei Zhou, Hongting Lu Published: 2025 ABSTRACT AbstractBackgroundWilms tumour is the most common paediatric renal malignancy. The RNA demethylase alkylation repair homologue protein 5 (ALKBH5), known for its role in reversing N6-methyladenosine modification, has been increasingly implicated in tumourigenesis. Its specific role in Wilms tumour, however, remains largely unexplored. We conducted a case–control study to investigate the association between ALKBH5 gene polymorphisms and susceptibility to Wilms tumour.MethodsOur study included 416 patients and 936 cancer-free controls from East China. We genotyped two ALKBH5 single-nucleotide polymorphisms: rs1378602 G>A and rs8400 G>A.ResultsWe found that the rs8400 AA genotype was significantly associated with an increased risk of Wilms tumour compared with GG/GA carriers (adjusted OR=1.39, 95% CI 1.04 to 1.85, p=0.025). Furthermore, individuals carrying two risk genotypes faced a significantly higher risk than those with zero or one risk genotype (adjusted OR=1.43, 95% CI 1.07 to 1.92, p=0.017). Stratified analysis revealed that this elevated risk was particularly pronounced in specific subgroups: children older than 18 months, females and those diagnosed with clinical stages I and II.ConclusionOur findings suggest that the ALKBH5 rs8400 G>A polymorphism is associated with increased susceptibility to Wilms tumour in the Eastern Chinese paediatric population.Keywords: Nephrology WHAT IS ALREADY KNOWN ON THIS TOPIC Wilms tumour is the most common paediatric renal malignancy, but the role of the RNA demethylase alkylation repair homologue protein 5 (ALKBH5) in its development remains unclear. Wilms tumour is the most common paediatric renal malignancy, but the role of the RNA demethylase alkylation repair homologue protein 5 (ALKBH5) in its development remains unclear. WHAT THIS STUDY ADDS Our case–control study demonstrates that the ALKBH5 rs8400 AA genotype significantly increases Wilms tumour risk in Eastern Chinese children, particularly in older, female and early stage subgroups. Our case–control study demonstrates that the ALKBH5 rs8400 AA genotype significantly increases Wilms tumour risk in Eastern Chinese children, particularly in older, female and early stage subgroups. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY These results identify ALKBH5 polymorphism as a novel genetic risk factor, advancing our understanding of Wilms tumour aetiology. This finding may inform future genetic screening strategies and personalised prevention approaches for high-risk populations. These results identify ALKBH5 polymorphism as a novel genetic risk factor, advancing our understanding of Wilms tumour aetiology. This finding may inform future genetic screening strategies and personalised prevention approaches for high-risk populations. Introduction Wilms tumour is the most common malignant tumour of embryonic kidney in children. The majority of patients are under 15 years old, with an average age of 5 years old.1 The incidence and survival rates of Wilms tumour are subject to variation based on geographic region, socioeconomic status and ethnic background. The incidence rate in western countries is higher than that in China, but this may be related to insufficient data collection.2 The survival rate of Wilms tumour in Western countries has exceeded 90%, except for children with poor histology, advanced disease, bilateral disease and recurrent Wilms tumour.3 In addition, the side effects of chemotherapy drug treatment cannot be ignored, with approximately 25% of Wilms tumour survivors suffering from chronic health problems, such as kidney failure, heart disease and secondary malignant tumours.4 5 The identified Wilms tumour susceptibility genes include WDR4, WT1, BARD1, XPD and TRIM28.6,9 However, the pathogenesis of Wilms tumour remains unclear so far. The systematic identification and validation of genetic variations are crucial for elucidating the underlying mechanisms of Wilms tumour and represent a critical step towards the long-term goal of developing targeted therapeutics. The N6-Methyladenosine (m6A) modification is the most abundant among eukaryotic gene modifications.10 m6A-dependent mRNA modification regulates RNA splicing, translocation, stability and translation into proteins and affects various biological processes, including self-renewal and differentiation, tissue development, DNA damage response, primary microRNA processing and RNA protein interactions.11 The reversible nature of m6A modification is dependent on a regulatory system comprising methyltransferases, demethylases and specific m6A-binding proteins. Studies had shown that these proteins are frequently upregulated in various human cancers and may play a vital role in the process of carcinogenesis.12 Alkylation repair homologue protein 5 (ALKBH5) is an RNA demethylase that belongs to the AlkB family and primarily catalyses the removal of m6A modifications. ALKBH5 is involved in the progression of many tumours. Overexpression of ALKBH5 makes pancreatic cancer cells sensitive to gemcitabine therapy and inhibits the occurrence of pancreatic cancer by reducing the m6A level of WIF-1 and inhibiting the activation of Wnt signalling.13 The demethylase activity of ALKBH5 plays a positive regulatory role in gastric cancer metastasis by enhancing the expression of PKMYT1.14 The ALKBH5–HOXA10 loop jointly activates the JAK2/STAT3 signalling pathway by mediating JAK2 m6A demethylation, promoting epithelial ovarian cancer resistance to cisplatin.15 ALKBH5 enhances the stability of DDX24 by upregulating the expression of LINC02551 to promote the growth and metastasis of hepatocellular carcinoma.16 Despite the emerging role of ALKBH5 in cancer, the influence of its functional gene polymorphisms on Wilms tumour susceptibility remains largely unexplored. To address this, we designed a case–control study to evaluate this relationship. Methods Genotyping According to the standard criteria described in the previous studies, we selected two potentially functional single-nucleotide polymorphisms (SNPs) in the ALKBH5 gene (rs1378602 and rs8400).17 In short, the criteria are as follows: (1) located at ALKBH5 gene (ie, 5’proximal gene, 5’UTR, 3’UTR and 3’proximal gene); (2) the frequency of minor alleles reported by Han Chinese participants in 1000 genomes is ≥5% (https://www.ncbi.nlm.nih.gov/variation/tools/1000genomes/); and (3) affect the activity of transcription factor-binding sites or miRNA-binding sites. Extract genomic DNA from the blood of participants. Genotyping of rs1378602 and rs8400 SNPs in the sample was performed using a customised ABI 7900 HT sequence detection system (Applied Biosystems). Rigorous quality control measures were implemented during genotyping. This included the use of no-template negative controls and a blinded repeat analysis of 10% of the samples to assess genotyping reproducibility, which achieved 100% concordance. Statistical analysis We employed the χ² goodness-of-fit test to verify that control genotype frequencies were in Hardy–Weinberg equilibrium (HWE). Additionally, a two-sided χ² test was applied to evaluate differences in demographic characteristics and allele frequency distributions between the case and control groups. Multivariate logistic regression analysis was performed in order to calculate adjusted ORs, 95% CIs and two-sided p values for evaluating the strength of association between each genotype and Wilms tumour risk. Expression quantitative trait locus (eQTL) analysis was performed using data from the genotype-tissue expression (GTEx) portal to assess whether significant SNPs influence the expression of their associated or proximal genes (https://gtexportal.org). The threshold with statistical significance is defined as p<0.05. All statistical analyses were conducted using SAS 9.1 software (SAS Institute, Cary, NC, USA). Patient and public involvement This research was a hospital-based case–control study. The research questions and outcome measures were primarily determined based on the literature review and laboratory feasibility, and were not directly formulated by patients or the public. However, patients and their families were involved in the research process. At the recruitment stage, doctors fully communicated the research purpose, procedures and potential implications to the parents or guardians of the children. We collected clinical data and specimens from paediatric patients in Qingdao, Anhui, Nanchang, Wenzhou, Fuzhou, Guangzhou, Nanjing and Xinjiang. Participation was entirely voluntary, and written informed consent was obtained from all parents or guardians before enrolment. Patients and the public contributed to this research by providing blood samples for genotyping. Due to the genetic and observational nature of this study, patients were not involved in evaluating the intervention burden or in the development of the study design. The results of this study will be disseminated through scientific publications. We also plan to share the main findings with the participating hospitals and suggest they inform interested participants on request. Results Association between ALKBH5 gene polymorphisms and Wilms tumour susceptibility Patient characteristics have been described previously. The associations between ALKBH5 polymorphisms and Wilms tumour susceptibility are presented in table 1. Successful genotyping for rs1378602 and rs8400 was achieved in all 416 cases and 936 controls. The genotype distributions for both SNPs in controls conformed to HWE (rs1378602, p=0.052 and rs8400, p=0.063). Of the two SNPs analysed, only the rs8400 AA genotype demonstrated a significant association with increased susceptibility to Wilms tumour (adjusted OR=1.39, 95% CI 1.04 to 1.85, p=0.025). A significant gene-dosage effect was observed. Subjects carrying two risk genotypes exhibited a significantly increased susceptibility to Wilms tumour compared with those with zero or one risk genotype (adjusted OR=1.43, 95% CI 1.07 to 1.92, p=0.017). Table 1Association between ALKBH5 gene polymorphisms and Wilms tumour susceptibility in children from East ChinaGenotypeCases(N=415)Controls(N=936)P*Crude OR(95% CI)PAdjusted OR(95% CI)†P†rs1378602 (HWE=0.052)GG349 (84.10)794 (82.69)1.001.00GA61 (14.70)149 (15.92)0.91 (0.66 to 1.26)0.5590.91 (0.66 to 1.26)0.561AA5 (1.20)13 (1.39)0.85 (0.30 to 2.41)0.7640.86 (0.30 to 2.42)0.771Additive0.5210.91 (0.69 to 1.21)0.5210.91 (0.69 to 1.21)0.525Dominant66 (15.90)162 (17.31)0.5250.90 (0.66 to 1.24)0.5250.90 (0.66 to 1.24)0.528GG/GA410 (98.80)923 (98.61)1.001.00AA5 (1.20)13 (1.39)0.7860.87 (0.31 to 2.45)0.7860.87 (0.31 to 2.46)0.792rs8400 (HWE=0.063)GG135 (32.53)285 (30.45)1.001.00GA186 (44.82)488 (52.14)0.81 (0.62 to 1.05)0.1090.80 (0.62 to 1.05)0.105AA94 (22.65)163 (17.41)1.22 (0.88 to 1.69)0.2371.22 (0.88 to 1.68)0.242Additive0.4431.07 (0.90 to 1.26)0.4431.07 (0.90 to 1.26)0.452Dominant280 (67.47)651 (69.55)0.4460.91 (0.71 to 1.16)0.4460.91 (0.71 to 1.16)0.437GG/GA321 (77.35)773 (82.59)1.001.00AA94 (22.65)163 (17.41)0.024 1.39 (1.04 to 1.85) 0.024 1.39 (1.04 to 1.85) 0.025 Risk genotypes‡0–1326 (78.55)786 (83.97)1.001.00289 (21.45)150 (16.03)0.016 1.43 (1.07 to 1.92) 0.016 1.43 (1.07 to 1.92) 0.017 The bold values indicates the positive results, which plays a prominent role.*χ2 test for genotype distributions between Wilms tumour cases and cancer-free controls.†Adjusted for age and gender.‡Risk genotypes were carriers with rs1378602 GG/GA and rs8400 AA.ALKBH5, alkylation repair homologue protein 5; HWE, Hardy–Weinberg equilibrium. Association between ALKBH5 gene polymorphisms and Wilms tumour susceptibility in children from East China The bold values indicates the positive results, which plays a prominent role. χ2 test for genotype distributions between Wilms tumour cases and cancer-free controls. Adjusted for age and gender. Risk genotypes were carriers with rs1378602 GG/GA and rs8400 AA. ALKBH5, alkylation repair homologue protein 5; HWE, Hardy–Weinberg equilibrium. Stratification analysis To assess potential effect modification, we performed stratified analyses by age, gender and clinical stage. The associations between ALKBH5 polymorphisms and Wilms tumour risk across these subgroups are detailed in table 2. We found that a statistically significant association between the rs8400 AA genotype increased the susceptibility to Wilms tumour in the specific subgroups of children older than 18 months (adjusted OR=1.62, 95% CI 1.12 to 2.33, p=0.010), females (adjusted OR=1.59, 95% CI 1.05 to 2.40, p=0.028) and patients with clinical stage I+II (adjusted OR=1.45, 95% CI 1.05 to 2.02, p=0.026). Meanwhile, in children aged over 18 months (adjusted OR=1.62, 95% CI 1.11 to 2.37, p=0.012), females (adjusted OR=1.53, 95% CI 1.01 to 2.33, p=0.046) and patients with clinical stage I+II (adjusted OR=1.48, 95% CI 1.05 to 2.07, p=0.024) carriers with two risk genotypes were more likely to develop Wilms tumour than carriers of 0–1 risk genotype. Table 2Stratification analysis for the association between ALKBH5 gene polymorphisms and Wilms tumour susceptibilityVariablesrs1378602(cases/controls)AOR (95% CI)*P*rs8400(cases/controls)AOR (95% CI)*P*Risk genotypes(cases/controls)AOR (95% CI)*P*GGGA/AAGG/GAAA0–12Age, month≤18119/34023/641.05 (0.62 to 1.76)0.864111/32531/791.14 (0.72 to 1.83)0.575112/33230/721.22 (0.76 to 1.97)0.407>18230/43443/980.83 (0.56 to 1.22)0.340210/44863/84 1.62 (1.12 to 2.33) 0.010 214/45459/78 1.62 (1.11 to 2.37) 0.012 GenderFemales154/34430/611.12 (0.70 to 1.82)0.635135/33049/75 1.59 (1.05 to 2.40) 0.028 138/33346/72 1.53 (1.01 to 2.33) 0.046 Males195/43036/1010.79 (0.52 to 1.19)0.259186/44345/881.23 (0.83 to 1.83)0.310188/45343/781.34 (0.89 to 2.02)0.162Clinical stagesI+II228/77441/1620.87 (0.60 to 1.27)0.482205/77364/163 1.45 (1.05 to 2.02) 0.026 209/78660/150 1.48 (1.05 to 2.07) 0.024 III+IV93/77422/1621.07 (0.65 to 1.76)0.79693/77322/1631.14 (0.69 to 1.88)0.60193/78622/1501.26 (0.77 to 2.08)0.364*Adjusted for age and gender.ALKBH5, alkylation repair homologue protein 5; AOR, adjusted OR. Stratification analysis for the association between ALKBH5 gene polymorphisms and Wilms tumour susceptibility Adjusted for age and gender. ALKBH5, alkylation repair homologue protein 5; AOR, adjusted OR. Effect of rs8400 on the expression of the ALKBH5 gene We conducted an eQTL analysis leveraging public data from the GTEx project. The analysis revealed that, in whole blood, the AA genotype at rs8400 resulted in significantly higher ALKBH5 mRNA expression compared with the combined GG/GA genotypes (p=6.44e-6, figure 1). Consistently, functional analysis in cultured fibroblast cells confirmed that the rs8400 AA genotype was associated with elevated ALKBH5 mRNA levels relative to the GG/GA genotypes (p=3.43e-16). Effect of rs8400 on the expression of the ALKBH5 gene. (A) The expression of the ALKBH5 gene in cultured fibroblast cells. (B) The expression of the ALKBH5 gene in whole blood. ALKBH5, alkylation repair homologue protein 5. Discussion This case–control study of 416 patients and 936 controls investigated the association between ALKBH5 polymorphisms and Wilms tumour susceptibility. We identified the rs8400 G>A polymorphism as a significant risk factor. Furthermore, the elevated risk associated with the rs8400 AA genotype was particularly pronounced in specific subgroups, including females, children older than 18 months and those with early stage disease (clinical stage I+II). In stratified analyses, carriers of two risk genotypes demonstrated significantly increased Wilms tumour susceptibility compared with those with zero or one risk genotype in the following subgroups: children over 18 months of age, females and patients with clinical stage I+II disease. To the best of our knowledge, this is the first study to systematically evaluate the association between ALKBH5 gene polymorphisms and Wilms tumour susceptibility in children from this region. There are currently over 170 known RNA post-transcriptional modifications, among which m6A is the most abundant RNA modification so far.18 50 years ago, m6A was first discovered and considered the most common internal modification of polyadenylated mRNAs in most eukaryotes.19 The development of m6A sequencing technology based on the next-generation sequencing has revealed that this modification is present in almost all types of RNA, such as mRNAs, microRNAs, long non-coding RNAs, circular RNAs, ribosomal RNAs and small nuclear RNAs.20 21 m6A is dynamically regulated by RNA methyltransferase (‘writer’) and demethylase (‘eraser’). Among them, the removal of m6A from RNA can be achieved through m6A demethylase, including fat mass and obesity-associated protein (FTO) and alpha-ketoglutarate-dependent dioxygenase ALKBH5.22 As a dynamic and reversible RNA modification, m6A acts as a key regulator of gene expression. For example, m6A regulates mRNA splicing, promotes mRNA nuclear export, alters mRNA stability, improves translation efficiency and promotes non-canonical translation initiation.23,25 There are currently nine members of the alkB family known to humans, including ALKBH1-8 and FTO, which share the same 2-oxoglutarate (also known as α-KG) oxygenase double-stranded β-spiral and its associated 20G and iron-binding sites, but with different reaction substrates and functions.26 ALKBH5 is a member of the well-conserved AlkB family of non-haeme Fe(II)/α-KG-dependent dioxygenases, which mediate the repair of N-alkylated nucleobases through oxidative demethylation.17 Research has found that ALKBH5 is only responsible for catalysing the removal of m6A from single-stranded RNAs. ALKBH5 preferentially interacts with the distal 5′ region of the coding sequence and has a specific preference for the shared sequence Pu (G>A) m6AC (A/C/U) (Pu is any purine base).27 Emerging evidence has established the significance of ALKBH5 as an m6A demethylase in epigenetic regulation and its critical impact on cancer progression. Some studies showed that the overexpression of ALKBH5 inhibited the tumour growth of oesophageal cancer, thyroid cancer and pancreatic cancer.28,30 On the contrary, ALKBH5 has also been reported to promote cancer progression in ovarian cancer, hepatocellular carcinoma and lung cancer through m6A demethylation.31,33 The m6A demethylation of GLUT4 mRNA mediated by ALKBH5 promotes resistance to HER2 targeted therapy, and targeting the ALKBH5/GLUT4 axis has therapeutic potential for patients with cancer who are refractory to HER2 targeted therapy.34 ALKBH5 activates the ERK/JNK (Extracellular signal-Regulated Kinase pathway,c-Jun N-terminal kinase pathway) pathway and regulates the expression of IL-8 by regulating the stability of MAP3K8, thereby promoting the proliferation and metastasis of hepatocellular carcinoma.35 These findings collectively suggest that ALKBH5 acts as a tumour-promoting factor, providing a rationale for the development of novel anticancer therapeutics. Our findings indicate that the rs8400 G>A polymorphism significantly increases the risk of Wilms tumour in children from this region. This study provides the initial evidence linking ALKBH5 polymorphisms to Wilms tumour susceptibility in Chinese children. Research has shown that ALKBH5 can regulate the epigenetic transcriptomics of tumours, leading to changes in cell proliferation, survival, invasion and metastasis, drug sensitivity, cancer stem cell status and cancer immunity. Therefore, we speculate that the same pathogenesis may also exist in Wilms tumour. Our research findings suggest that rs8400 G>A may lead to increased susceptibility to Wilms tumour. In contrast, the rs1378602 G>A polymorphism showed no significant association with Wilms tumour risk. This study has several limitations that should be considered. The sample size, while substantial, may have limited the power to establish reliable associations for genetic variants with smaller effect sizes. Future studies with larger cohorts are needed to enhance statistical power and validate these findings. Second, our analysis was restricted to two ALKBH5 SNPs; a more comprehensive investigation of potential functional polymorphisms is warranted. Third, as all participants were of Chinese descent, the generalisability of our findings to other ethnic populations requires validation. Finally, this study focused solely on genetic susceptibility, precluding the assessment of potential interactions with environmental factors. Our findings demonstrate that the ALKBH5 rs8400 G>A polymorphism is a significant risk factor for Wilms tumour, laying the groundwork for future research. Expanding the sample size and incorporating diverse ethnic and environmental contexts will be essential to achieve a more comprehensive understanding of the disease aetiology. Supplementary material Footnotes Funding: This study was funded by grants from the Natural Science Foundation of Shandong Province (No: ZR2020MH213) and Youth Medical Innovation and Practice Research Programme of Guangzhou (No: 2023QNYXYB010). Provenance and peer review: Not commissioned; externally peer reviewed. Patient consent for publication: Not applicable. Ethics approval: Wilms tumortumour cases were recruited from six hospitals across the provinces of Shandong, Anhui, Zhejiang, Jiangxi, Fujian, and Jiangsu. A total of 416 histologically verified Wilms tumortumour cases and 936 cancer-free controls were enrolled in this case-–control study (online supplemental table S1). Cancer-free controls, who were matched to the patients on age, gender, and ethnicity, were enrolled from the same hospitals concurrently and were negative for any family history of Wilms tumortumour. This study was conducted in accordance with the Declaration of Helsinki and was approved by the Institutional Review Committee of Qingdao Women and Children’s Hospital (Approval No. QFELL-YJ-2024–208). Written informed consent was obtained from all parents or guardians. Patient and public involvement: Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research. Data availability statement Data are available on reasonable request. References Supplementary Materials Data Availability Statement Data are available on reasonable request.